Ken Griffin Cullinan Oncology, Inc. Put Options Transaction History

Citadel Advisors LLC

11 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q2 2025 Aug 14, 2025	BUY	$7.13 - $9.08 $1.04 Million - $1.33 Million	146,000 Added 815.64%	163,900 $1.23 Million
Q1 2025 May 15, 2025	SELL	$7.57 - $12.68 $32,551 - $54,524	-4,300 Reduced 19.37%	17,900 $135,000
Q4 2024 Feb 14, 2025	SELL	$10.77 - $17.6 $66,774 - $109,120	-6,200 Reduced 21.83%	22,200 $270,000
Q3 2024 Nov 14, 2024	BUY	$16.03 - $20.86 $200,375 - $260,750	12,500 Added 78.62%	28,400 $475,000
Q2 2024 Aug 14, 2024	BUY	$15.63 - $29.35 $171,930 - $322,850	11,000 Added 224.49%	15,900 $277,000
Q1 2024 May 15, 2024	SELL	$10.17 - $19.02 $25,425 - $47,550	-2,500 Reduced 33.78%	4,900 $83,000
Q4 2023 Feb 14, 2024	BUY	$7.89 - $10.23 $26,826 - $34,782	3,400 Added 85.0%	7,400 $75,000
Q3 2023 Nov 14, 2023	BUY	$9.05 - $11.72 $17,195 - $22,268	1,900 Added 90.48%	4,000 $36,000
Q2 2023 Aug 14, 2023	BUY	$8.8 - $13.4 $5,280 - $8,040	600 Added 40.0%	2,100 $22,000
Q1 2023 May 15, 2023	BUY	$10.2 - $11.91 $12,240 - $14,292	1,200 Added 400.0%	1,500 $15,000
Q4 2022 Feb 14, 2023	BUY	$9.72 - $13.62 $2,916 - $4,085	300 New	300 $3,000

154

67.7M

10.6K

917K

Ticker CGEM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 45,612,200
Market Cap $332M
Description
Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.